Published in Am J Surg Pathol on May 01, 2006
Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients. J Am Coll Surg (2013) 2.12
Pseudomyxoma peritonei. World J Gastrointest Oncol (2010) 1.76
Prognostic Molecular Subtypes of Low-Grade Cancer of the Appendix. J Am Coll Surg (2015) 1.39
A new standard of care for the management of peritoneal surface malignancy. Curr Oncol (2011) 1.20
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol (2012) 1.12
Immunohistochemical features of the gastrointestinal tract tumors. J Gastrointest Oncol (2012) 1.06
Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. Ann Surg (2013) 1.05
FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma. Oncologist (2014) 1.00
Pseudomyxoma peritonei: is disease progression related to microbial agents? A study of bacteria, MUC2 AND MUC5AC expression in disseminated peritoneal adenomucinosis and peritoneal mucinous carcinomatosis. Ann Surg Oncol (2008) 0.97
Gene expression profiling of peritoneal metastases from appendiceal and colon cancer demonstrates unique biologic signatures and predicts patient outcomes. J Am Coll Surg (2012) 0.96
Pseudomyxoma peritonei: a need to establish evidence-based standard of care--is this the right trial? Ann Surg Oncol (2009) 0.95
Peritoneal surface disease (PSD) from appendiceal cancer treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC): overview of 481 cases. Ann Surg Oncol (2014) 0.95
Mucinous adenocarcinomas with intra-abdominal dissemination: a review of current therapy. Oncologist (2010) 0.88
Clinicopathological analysis of primary epithelial appendiceal neoplasms. Med Oncol (2009) 0.87
Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Surg Oncol (2013) 0.87
The impact of stage, grade, and mucinous histology on the efficacy of systemic chemotherapy in adenocarcinomas of the appendix: Analysis of the National Cancer Data Base. Cancer (2015) 0.85
Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype. BMC Cancer (2007) 0.85
Challenges of efficacy assessments in pseudomyxoma peritonea. Oncologist (2015) 0.84
Low grade peritoneal mucinous carcinomatosis associated with human papilloma virus infection: case report. Croat Med J (2008) 0.83
Significance of signet ring cells in high-grade mucinous adenocarcinoma of the peritoneum from appendiceal origin. Hum Pathol (2014) 0.82
Establishment and characterization of a murine xenograft model of appendiceal mucinous adenocarcinoma. Int J Exp Pathol (2010) 0.82
Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer Med (2015) 0.82
Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin/fluorouracil/leucovorin (FOLFOX4). World J Surg Oncol (2008) 0.81
Surgical cytoreduction and intraperitoneal chemotherapy for peritoneal carcinomatosis arising from the appendix. Can J Surg (2009) 0.81
Outcome of patients with aggressive pseudomyxoma peritonei treated by cytoreductive surgery and intraperitoneal chemotherapy. World J Surg (2013) 0.78
Pseudomyxoma peritonei of 92 Chinese patients: clinical characteristics, pathological classification and prognostic factors. World J Gastroenterol (2012) 0.78
Low-Grade Appendiceal Mucinous Neoplasm Presenting as a Surgical Emergency: A Case Report. Case Rep Oncol (2009) 0.78
Chronic anti-inflammatory drug therapy inhibits gel-forming mucin production in a murine xenograft model of human pseudomyxoma peritonei. Ann Surg Oncol (2012) 0.77
Conditional Survival After Cytoreductive Surgery with Heated Intraperitoneal Chemotherapy for Low- and High-Grade Appendiceal Primaries. Ann Surg Oncol (2015) 0.77
Cytoreductive surgery with intraperitoneal chemotherapy to treat pseudomyxoma peritonei at nonspecialized hospitals. Surg Today (2011) 0.76
Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy-current perspectives. Curr Oncol (2016) 0.76
Carbohydrate antigen 19-9 (CA 19-9) is an independent prognostic indicator in pseudomyxoma peritonei post cytoreductive surgery and perioperative intraperitoneal chemotherapy. J Gastrointest Oncol (2013) 0.76
GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. J Transl Med (2016) 0.76
Peritoneal carcinomatosis of gastrointestinal tumors: where are we now? World J Gastroenterol (2014) 0.76
Drug Sensitivity Testing in Cytoreductive Surgery and Intraperitoneal Chemotherapy of Pseudomyxoma Peritonei. Ann Surg Oncol (2015) 0.75
Pseudomyxoma cutis; a new entity. Int J Clin Exp Pathol (2013) 0.75
Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report. BMC Med Genet (2016) 0.75
Large mucinous neoplasm of the appendix mimicking adnexal mass in a postmenopausal woman. Int J Surg Case Rep (2014) 0.75
Transformation of low-grade mucinous neoplasm of the appendix with pseudomyxoma peritonei to high-grade sarcomatoid carcinoma. J Clin Med Res (2015) 0.75
Pseudomyxoma peritonei: A rose by any other name... Am J Surg Pathol (2006) 0.75
Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment. Cancer Med (2016) 0.75
Pseudomyxoma peritonei extending to the lower extremity: a case report. World J Surg Oncol (2015) 0.75
Role of Imaging in Peritoneal Surface Malignancies. Indian J Surg Oncol (2016) 0.75
High-quality results of cytoreductive surgery and heated intraperitoneal chemotherapy perfusion for carcinomatosis at a low volume institution. J Surg Oncol (2015) 0.75
Significance of serum tumor marker levels in peritoneal carcinomatosis of appendiceal origin. Ann Surg Oncol (2012) 0.75
Hyperthermic intraperitoneal chemotherapy with oxaliplatin as treatment for peritoneal carcinomatosis arising from the appendix and pseudomyxoma peritonei: a survival analysis. World J Surg Oncol (2014) 0.75
Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: review of indications and outcomes. J Gastrointest Oncol (2016) 0.75
The importance of gender in patients with peritoneal metastases of appendiceal origin treated by cytoreduction and intraperitoneal chemotherapy: an analysis of 257 consecutive patients from an Australian centre. J Cancer Res Clin Oncol (2014) 0.75
[Mucinous neoplasms of the vermiform appendix, Pseudomyxoma peritonei, and the new WHO classification]. Pathologe (2012) 0.75
Stratification of outcomes for mucinous appendiceal adenocarcinoma with peritoneal metastasis by histological grade. World J Gastrointest Oncol (2017) 0.75
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified? Clin Transl Oncol (2017) 0.75
Appendiceal Mucinous Neoplasms: Diagnosis and Management. Oncologist (2017) 0.75
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol (2007) 7.73
Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol (2012) 5.06
Cancer incidence before and after kidney transplantation. JAMA (2006) 4.77
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
Results of valve replacement with Omniscience mechanical prostheses. Ann Thorac Surg (2002) 2.66
Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol (2007) 2.46
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy with mitomycin C for peritoneal carcinomatosis from nonappendiceal colorectal carcinoma. Ann Surg Oncol (2004) 2.30
Transocular entry of seasonal influenza-attenuated virus aerosols and the efficacy of n95 respirators, surgical masks, and eye protection in humans. J Infect Dis (2011) 2.22
Glycated albumin and risk of death and hospitalizations in diabetic dialysis patients. Clin J Am Soc Nephrol (2011) 2.19
Vulvar seborrheic keratosis: is there a relationship to human papillomavirus? J Low Genit Tract Dis (2014) 2.14
Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial. J Clin Oncol (2013) 2.12
Appendiceal neoplasms with peritoneal dissemination: outcomes after cytoreductive surgery and intraperitoneal hyperthermic chemotherapy. Ann Surg Oncol (2006) 2.06
Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. J Thorac Oncol (2014) 2.04
Cytoreductive surgery and intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: experience with 501 procedures. J Am Coll Surg (2007) 1.85
Long-term survivorship and quality of life after cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol (2003) 1.81
Pesticide safety among farmworkers: perceived risk and perceived control as factors reflecting environmental justice. Environ Health Perspect (2002) 1.78
High-resolution fluorodeoxyglucose positron emission tomography with compression ("positron emission mammography") is highly accurate in depicting primary breast cancer. Breast J (2006) 1.76
Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol (2010) 1.69
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol (2005) 1.69
Use of a new method in reaching consensus on the cause of cytologic-histologic correlation discrepancy. Am J Clin Pathol (2006) 1.68
Restorative yoga for women with breast cancer: findings from a randomized pilot study. Psychooncology (2009) 1.65
Polygenic model of DNA repair genetic polymorphisms in human breast cancer risk. Carcinogenesis (2008) 1.64
Futility of fluorodeoxyglucose F 18 positron emission tomography in initial evaluation of patients with T2 to T4 melanoma. Arch Surg (2006) 1.59
Use of short tandem repeats for DNA fingerprinting to rapidly diagnose graft-versus-host disease in solid organ transplant patients. Transplantation (2006) 1.54
E-cadherin-negative primary small cell carcinoma of the breast. Report of a case and review of the literature. Am J Clin Pathol (2004) 1.46
Percutaneous radiofrequency ablation of hepatic metastases for symptomatic relief of neuroendocrine syndromes. AJR Am J Roentgenol (2003) 1.45
Comparison of glycated albumin and hemoglobin A1c concentrations in diabetic subjects on peritoneal and hemodialysis. Perit Dial Int (2010) 1.45
Factors predicting survival after intraperitoneal hyperthermic chemotherapy with mitomycin C after cytoreductive surgery for patients with peritoneal carcinomatosis. Arch Surg (2003) 1.45
Intraperitoneal hyperthermic chemotherapy for peritoneal surface malignancy: current status and future directions. Ann Surg Oncol (2005) 1.44
Soft tissue amyloidoma of the extremities: a case report and review of the literature. Arch Pathol Lab Med (2004) 1.43
Peritoneal carcinomatosis: cytoreductive surgery and HIPEC--overview and basics. Cancer Invest (2012) 1.42
Plasma FGF23 and Calcified Atherosclerotic Plaque in African Americans with Type 2 Diabetes Mellitus. Am J Nephrol (2015) 1.42
Treatment of in-transit metastases from Merkel cell carcinoma with isolated hyperthermic limb perfusion. Am Surg (2007) 1.40
Tubercular scrotal disease. Acta Cytol (2006) 1.39
Leiomyosarcoma of the inferior vena cava: surgical management and clinical results. Am Surg (2005) 1.31
Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. J Thorac Oncol (2006) 1.31
Effects of age, gender, bolus condition, viscosity, and volume on pharyngeal and upper esophageal sphincter pressure and temporal measurements during swallowing. J Speech Lang Hear Res (2008) 1.27
Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation. Blood (2009) 1.23
Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol (2010) 1.22
Cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for advanced gastric cancer. J Gastrointest Surg (2004) 1.22
DNA-repair genetic polymorphisms and breast cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.20
Loss of expression of tropomyosin-1, a novel class II tumor suppressor that induces anoikis, in primary breast tumors. Oncogene (2003) 1.20
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: overview and rationale. Curr Probl Cancer (2009) 1.19
Outcomes of Cytoreductive Surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol (2013) 1.19
Effect of reduced immunosuppression after kidney transplant failure on risk of cancer: population based retrospective cohort study. BMJ (2010) 1.18
Longitudinal analysis of one million vital signs in patients in an academic medical center. Resuscitation (2011) 1.18
A novel automated assay for the rapid identification of metastatic breast carcinoma in sentinel lymph nodes. Cancer (2011) 1.14
Relationship between assays of glycemia in diabetic subjects with advanced chronic kidney disease. Am J Nephrol (2010) 1.12
Intraoperative evaluation of lumpectomy margins by imprint cytology with histologic correlation: a community hospital experience. Arch Pathol Lab Med (2002) 1.12
Survival and health outcomes after cytoreductive surgery with intraperitoneal hyperthermic chemotherapy for disseminated peritoneal cancer of appendiceal origin. Ann Surg Oncol (2007) 1.10
Urine cytology discrepancies: frequency, causes, and outcomes. Am J Clin Pathol (2007) 1.08
Survival disadvantage among Medicaid-insured breast cancer patients treated with breast conserving surgery without radiation therapy. Breast Cancer Res Treat (2006) 1.08
Sickle cell trait and development of microvascular complications in diabetes mellitus. Clin J Am Soc Nephrol (2010) 1.07
Rapid photothermal intracellular drug delivery using multiwalled carbon nanotubes. Mol Pharm (2009) 1.06
Peritoneal surface disease from colorectal cancer: comparison with the hepatic metastases surgical paradigm in optimally resected patients. Ann Surg Oncol (2008) 1.06
Neutrophil-rich Ki-1-positive anaplastic large cell lymphoma: a study by fine-needle aspiration biopsy. Am J Clin Pathol (2002) 1.05
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer (2010) 1.05
Cutaneous melanoma is related to immune suppression in kidney transplant recipients. Cancer Epidemiol Biomarkers Prev (2009) 1.05
Pleuropulmonary involvement in pseudomyxoma peritonei: morphologic assessment and literature review. Am J Clin Pathol (2007) 1.04
Adenocarcinoma of the appendix is rarely detected by colonoscopy. J Gastrointest Surg (2008) 1.03
Physical activity and reduced risk of incident sporadic colorectal adenomas: observational support for mechanisms involving energy balance and inflammation modulation. Am J Epidemiol (2004) 1.01
Predicting postoperative morbidity following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CS+HIPEC) with preoperative FACT-C (Functional Assessment of Cancer Therapy) and patient-rated performance status. Ann Surg Oncol (2013) 1.00
Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes (2002) 1.00
A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers. Ann Surg Oncol (2008) 1.00
Patterns of care analysis among women with ductal carcinoma in situ in North Carolina. Am J Surg (2008) 0.99
Survival and quality of life following cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis of colonic origin. Ann Surg Oncol (2011) 0.98
Prognostic Performance of Different Lymph Node Staging Systems After Curative Intent Resection for Gastric Adenocarcinoma. Ann Surg (2015) 0.98
Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology. Cancer (2002) 0.98
Yin Yang 1 plays an essential role in breast cancer and negatively regulates p27. Am J Pathol (2012) 0.98
Positron emission mammography: initial clinical results. Ann Surg Oncol (2003) 0.98
Virtual bronchoscopy for evaluation of malignant tumors of the thorax. J Thorac Cardiovasc Surg (2002) 0.97
Monitoring health outcomes following cytoreductive surgery plus intraperitoneal hyperthermic chemotherapy for peritoneal carcinomatosis. Ann Surg Oncol (2007) 0.97
Polymorphisms in drug metabolism genes, smoking, and p53 mutations in breast cancer. Mol Carcinog (2008) 0.96